PMID: 9537586Apr 16, 1998Paper

Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas

International Journal of Cancer. Journal International Du Cancer
W HelfrichL de Leij

Abstract

We describe the construction of a recombinant bispecific antibody fragment in the diabody format with specificity for both the well-established human pancarcinoma associated target antigen EGP2 (epithelial glycoprotein 2, also known as the CO17-1A antigen or KSA) and the CD3epsilon chain of human TCR/CD3 complex. The murine anti-EGP2 (MOC31) single chain variable fragment (scFv) and the humanized anti-CD3 (Ucht1v9) scFv were cast into a diabody format (designated Dia5v9) using a short 5 amino acid Gly-Ser linker between immunoglobulin heavy-chain and light-chain variable domains. Purification of the poly-histidine tagged Dia5v9 was achieved from extracts of protease deficient Escherichia coli by IMAC chromatography. The Dia5v9 diabody showed strong binding to both EGP2 and CD3 in transfected cells. The in vitro efficacy of Dia5v9 in mediating tumor cell lysis by interleukin-2 activated human T cells appeared to be similar to that of the hybrid-hybridoma-derived BsF(ab')2 Bis1 (anti-EGP2/anti-CD3) in a standard 4-hr 51Cr-release assay. This small and partially humanized recombinant bispecific antibody fragment may be valuable for T-cell-based immunotherapeutical treatment protocols, retargeting activated peripheral blood T lymph...Continue Reading

References

Aug 15, 1991·Nature·T ClacksonG Winter
Jan 1, 1994·International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement·L De LeijM J Mattes
Jan 1, 1994·International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement·W HelfrichL De Leij
Jul 18, 1995·Proceedings of the National Academy of Sciences of the United States of America·M MackP Kufer
Dec 15, 1994·Structure·O PerisicR L Williams
Jan 1, 1995·Protein Engineering·A Knappik, A Plückthun
Jan 1, 1994·International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement·W HelfrichL De Leij
Jul 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·P HolligerG Winter
Jan 1, 1996·Springer Seminars in Immunopathology·R L BolhuisJ W Gratama
Jan 15, 1997·Journal of Immunological Methods·S M KipriyanovM Little
Feb 1, 1996·Immunotechnology : an International Journal of Immunological Engineering·A M WuJ E Shively
Sep 1, 1996·Nature Biotechnology·B T McGuinnessH R Hoogenboom

❮ Previous
Next ❯

Citations

Jan 15, 2008·The Journal of Pharmacology and Experimental Therapeutics·Eric C PetersonS Michael Owens
Nov 10, 2001·Annual Review of Biomedical Engineering·J Maynard, G Georgiou
Dec 9, 2000·Protein Engineering·A SchmiedlS Dübel
May 28, 2008·Molecular Nutrition & Food Research·Saravanan YuvarajNicolaas A Bos
Jul 16, 2008·Protein Engineering, Design & Selection : PEDS·Ryutaro AsanoIzumi Kumagai
Jun 4, 2002·Nature Biotechnology·Jennifer A MaynardGeorge Georgiou
Jan 22, 2005·Acta Pharmacologica Sinica·Roland E Kontermann
Nov 23, 2011·Chemical Society Reviews·Zimple MatharuBansi Dhar Malhotra
Jul 27, 1999·International Journal of Cancer. Journal International Du Cancer·O ManzkeH Bohlen
May 9, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·A M McCallL M Weiner
May 15, 2007·Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology·Nicolas Fischer, Olivier Léger
Oct 29, 2008·The Journal of Biological Chemistry·Hideki WatanabeIzumi Kumagai
Dec 18, 2009·The FEBS Journal·Ryutaro AsanoIzumi Kumagai
Jul 5, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ryutaro AsanoIzumi Kumagai
Jan 21, 2000·Journal of Controlled Release : Official Journal of the Controlled Release Society·G MolemaL F de Leij
Jul 20, 1999·Journal of Immunological Methods·R E Kontermann, R Müller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.